CDC2及PFTK1在食管鳞癌中的表达及其临床意义

《CDC2及PFTK1在食管鳞癌中的表达及其临床意义》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、-ABSTRACTexpressionofCDC2andPFTK1weresignificantlypositivelycorrelated(r=0.367,P=0.004)(P<0.05).Conclusion:1.ThepositiveexpressionofCDC2wasmainlylocatedincytoplasm,fewnuclearexpression,ThepositiveexpressionofPFTK1wasmainlylocatedincytoplasm,allpresentingaregionalordiffused

2、istribution.2.TheexpressionratesofCDC2andPFTK1proteinincancertissueswerehigherthanthoseinpara-canceroustissues,suggestingtheup-regulatedexpressionofCDC2andPFTK1maybeassociatedwiththeoccurrenceofesophagealsquamouscellcarcinoma.3.ThepositiveratesofCDC2andPFTK1inesophagealsqu

3、amouscellcorrelatedwithclinicalstages,depthoftumorinvasionandlymphnodemetastasis,butnotcorrelatedwithgender,age,degreeofdifferentiation(P>0.05).Showthatbothmightbeassociatedwithesophagealsquamouscellcarcinomainvasionandmetastasis4.ThepositiveratesexpressionofCDC2andPFTK1in

4、esophagealsquamouscellcarcinomawerepositivelycorrelated,suggestingthattheymayparticipateinthedevelopmentofesophagealsquamouscellcarcinoma.KEYWORDS:Cellcycle;CDC2;PFTK1;EsophagealsquamouscellcarcinomaDissertationType:ResearchSubjectSource:OthersIV----万方数据----目录目录第1章绪论......

5、...........................................11.1研究背景..............................................................................................................11.1.1食管癌的流行病学及病因学...................................................................11.1.2食管癌病理学特征及转移特性........

6、.......................................................21.1.3食管癌的临床表现及治疗现状...............................................................21.1.4细胞周期及相关分子...............................................................................31.1.5CDC2的生物学特性..........................

7、.....................................................101.1.6CDC2与肿瘤...........................................................................................111.1.7PFTK1的生物性特性.............................................................................141.1.8PFTK1与肿瘤.....

8、....................................................................................171.1